Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04809467 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
A Phase 1 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT04809467 is a Phase 1 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 54 participants.
The verdict
NCT04809467, a Phase 1 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely combined at the recommended Phase 2 dose (RP2D) and dosing regimen that was established for each of the 2 compounds as a treatment option for adult participants with R/R B-cell malignancies.
Interventions
- DRUG tafasitamab
- DRUG parsaclisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2024-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04809467
The ClinicalTrials.gov registry entry for NCT04809467 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tafasitamab is the first listed.
NCT04809467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04809467 about?
NCT04809467 is a clinical study titled "A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)". The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely combined at the recommended Phase 2 dose (RP2D) and dosing regimen that was established for each of the 2 compounds as a treatment option for adult parti...
What is the current status of trial NCT04809467?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2021-09-16. Estimated completion is 2024-10-22.
What interventions are being tested in trial NCT04809467?
The interventions under investigation include: tafasitamab (DRUG), parsaclisib (DRUG).
Who is sponsoring clinical trial NCT04809467?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.